BR112017025533A2 - método para tratar câncer em um paciente humano - Google Patents

método para tratar câncer em um paciente humano

Info

Publication number
BR112017025533A2
BR112017025533A2 BR112017025533A BR112017025533A BR112017025533A2 BR 112017025533 A2 BR112017025533 A2 BR 112017025533A2 BR 112017025533 A BR112017025533 A BR 112017025533A BR 112017025533 A BR112017025533 A BR 112017025533A BR 112017025533 A2 BR112017025533 A2 BR 112017025533A2
Authority
BR
Brazil
Prior art keywords
human patient
treat cancer
combination therapies
cancer
cpg
Prior art date
Application number
BR112017025533A
Other languages
English (en)
Inventor
Guiducci Cristiana
Keith Chartash Elliot
A Kastelein Robert
L Coffman Robert
S Janssen Robert
Sadekova Svetlana
Truong Phan Uyen
Yu Ying
Original Assignee
Dynavax Tech Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp, Merck Sharp & Dohme filed Critical Dynavax Tech Corp
Publication of BR112017025533A2 publication Critical patent/BR112017025533A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a presente descrição descreve terapias de combinação compreendendo um anticorpo anti-il-10 ou fragmento de ligação de antígeno do mesmo e um oligonucleotídeo tipo cpg-c, e o uso das terapias de combinação para o tratamento de câncer.
BR112017025533A 2015-05-29 2016-05-26 método para tratar câncer em um paciente humano BR112017025533A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168470P 2015-05-29 2015-05-29
US201562169321P 2015-06-01 2015-06-01
PCT/US2016/034285 WO2016196178A1 (en) 2015-05-29 2016-05-26 Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer

Publications (1)

Publication Number Publication Date
BR112017025533A2 true BR112017025533A2 (pt) 2018-08-07

Family

ID=57442233

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017025533A BR112017025533A2 (pt) 2015-05-29 2016-05-26 método para tratar câncer em um paciente humano

Country Status (12)

Country Link
US (1) US20180161427A1 (pt)
EP (1) EP3302554A4 (pt)
JP (1) JP2018516252A (pt)
KR (1) KR20180014010A (pt)
CN (1) CN107949399A (pt)
AU (1) AU2016271023A1 (pt)
BR (1) BR112017025533A2 (pt)
CA (1) CA2986232A1 (pt)
MA (1) MA44700A (pt)
MX (1) MX2017015311A (pt)
RU (1) RU2017145559A (pt)
WO (1) WO2016196178A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
JP2017537619A (ja) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ 球状核酸ナノ粒子複合体の配列特異的細胞内取込
RU2017145940A (ru) * 2015-05-29 2019-07-02 Дайнэвокс Текнолоджиз Корпорейшн Внутрилегочное введение полинуклеотидных агонистов толл-подобного рецептора 9 для лечения рака легких
EP3302501B1 (en) 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
EP1575977B1 (en) * 2002-12-23 2009-09-09 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
PE20090047A1 (es) * 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
WO2006086798A2 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
WO2007107349A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treament of cancer
JP2009016596A (ja) * 2007-07-05 2009-01-22 Elpida Memory Inc 半導体装置及び半導体装置の製造方法
EP2190440A1 (en) * 2007-08-13 2010-06-02 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity

Also Published As

Publication number Publication date
RU2017145559A (ru) 2019-07-03
US20180161427A1 (en) 2018-06-14
JP2018516252A (ja) 2018-06-21
MA44700A (fr) 2019-02-27
KR20180014010A (ko) 2018-02-07
CN107949399A (zh) 2018-04-20
MX2017015311A (es) 2018-06-19
CA2986232A1 (en) 2016-12-08
AU2016271023A1 (en) 2017-11-30
EP3302554A1 (en) 2018-04-11
EP3302554A4 (en) 2019-02-27
WO2016196178A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
BR112017010324A2 (pt) método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
BR112017008628A2 (pt) terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
GEP20217317B (en) Combination therapy for the treatment of cancer
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MA40364A (fr) Polythérapie pour le traitement du cancer
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112017002809A2 (pt) métodos para tratar câncer cervical
BR112015010220A2 (pt) métodos de utilização de biomarcadores para tratamento de câncer
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]